<DOC>
	<DOCNO>NCT00297583</DOCNO>
	<brief_summary>The primary objective study compare effect insulin glulisine , insulin lispro unmodified human insulin endogenous glucose production euglycemic glucose clamp use stable label glucose type 1 diabetic subject . The secondary objective study ass : - effect insulin glulisine , insulin lispro unmodified human insulin plasma nonesterified free fatty acid ( NEFA ) glycerol level - effect insulin glulisine , insulin lispro unmodified human insulin plasma lactate level - safety tolerability insulin glulisine comparison insulin lispro unmodified human insulin .</brief_summary>
	<brief_title>Insulin Glulisine Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion Type 1 diabetes ( define World Health Organization ) least 2 year HbA1c ≤ 10.0 % Cpeptide &lt; 0.05 nmol/L , base fast Cpeptide level Body mass index ( BMI ) ≤ 30 kg/m² Treatment intensify insulin therapy : short act insulin meal ( breakfast , lunch , dinner ) neutral protamine Hagedorn ( NPH ) insulin , continuous subcutaneous insulin infusion ( CSII ) least 3 months.Insulin glargine , basal insulin NPH , replace NPH insulin screen visit . Women childbearing potential ( surgically sterile , postmenopausal 2 year ) pregnant agree use reliable contraceptive measure duration study . Able willing perform selfmonitoring blood glucose Exclusion criterion Contraindications : The medical history physical examination Laboratory test ( hematology , clinical chemistry urinalysis ) 12lead electrocardiogram ( ECG ) Blood pressure pulse rate Hepatitis screen Pregnancy , breastfeed intention become pregnant History drug alcohol abuse Receipt investigational drug within last 30 day prior trial Experienced recurrent severe hypoglycemia hypoglycemic unawareness ( judged investigator ) Total daily insulin dose ≥ 1.4 IU/kg Serum insulin antibody level &gt; 20 U/mL determine screen visit Smokers &gt; 10 cigarette per day equivalent Preplanned surgery study Currently treat systemic corticosteroid drug affect blood glucose , immunosuppressives Known diabetic gastroparesis lipodystrophia Active proliferative diabetic retinopathy , define application focal panretinal photocoagulation vitrectomy , 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require surgical treatment ( include laser photocoagulation ) study Cardiac problem : New York Heart Association ( NYHA ) Functional Capacity Class III IV Diagnosis unstable angina pectoris Myocardial infarction within last 12 month Biochemical sign hepatic renal disease indicate alanine aminotransferase and/or alkaline phosphatase ≥ 2 time and/or creatinine ≥ 1.5 time upper limit normal reference range age group current renal dialysis Anemia indicate hemoglobin &lt; 6.2 mmol/L clinically relevant iron deficiency indicate low ferritin level men ( &lt; 34 ng/mL ) woman ( premenopausal &lt; 22 ng/mL , menopausal &lt; 13 ng/mL ) Any clinically significant major organ system disease relevant cardiovascular ( e.g . uncontrolled hypertension ) , gastrointestinal , hepatic , neurologic , endocrine ( e.g.pancreatic ) , hematologic , malignant major systemic disease make implementation protocol interpretation study result difficult Significant endogenous insulin secretion indicate fasting Cpeptide History hypersensitivity insulin insulin analogues excipients HMR Donation blood ( &gt; 500 mL ) previous 3 month prior screen visit duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>